Piribo

Piribo.com, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a report which analyses the pharmaceutical market in Romania, profiles the top companies and forecasts to 2010.

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a report which examines supply chain management (SCM) in the pharmaceutical industry in Poland 2008.

Piribo.com, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a report analysing the technique pharmaceutical companies use when reformulating prescription drugs as over-the counter medicines.

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a report which comprehensively analyses the prospects for the osteoporosis and bone metabolism industry from 2008-2023.

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report analysing drug delivery technologies.

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a report on cardiovascular drug delivery markets which provides forecasts to 2017.

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report which provides a detailed and thorough analysis of the present and future global market for cancer therapeutics.

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report analysing the OTC (drug Over- the - Counter) market in Central and Eastern Europe.

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a report which analyses how and why companies enter discovery stage licensing/business development partnering arrangements.

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a report offering readers vital information on the latest developments in, as well as future forecasts of, RNA interference.